Amy J. Eisenfeld

1.3k total citations
20 papers, 1.1k citations indexed

About

Amy J. Eisenfeld is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Amy J. Eisenfeld has authored 20 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 6 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Amy J. Eisenfeld's work include Cancer Treatment and Pharmacology (5 papers), Retinal Development and Disorders (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Amy J. Eisenfeld is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Retinal Development and Disorders (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Amy J. Eisenfeld collaborates with scholars based in United States, Germany and South Africa. Amy J. Eisenfeld's co-authors include Ann H. Bunt-Milam, P. Vijay Sarthy, John C. Saari, F. B. Oldham, Jennifer H. LaVail, Matthew M. LaVail, Scott Stromatt, Jack W. Singer, J C Saari and B. Bandstra and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Comparative Neurology.

In The Last Decade

Amy J. Eisenfeld

20 papers receiving 1.0k citations

Peers

Amy J. Eisenfeld
Aneeka Chaudhry United States
Shimpei Nishikawa Japan
José Courty France
Michael D. Barker United Kingdom
Mauricio Rosenfeld United States
Anthony M.P. Montgomery United States
Bithiah Grace Jaganathan India
Zahra‐Soheila Soheili Iran
Jung Min Lee South Korea
S. Clifford Schold United States
Aneeka Chaudhry United States
Amy J. Eisenfeld
Citations per year, relative to Amy J. Eisenfeld Amy J. Eisenfeld (= 1×) peers Aneeka Chaudhry

Countries citing papers authored by Amy J. Eisenfeld

Since Specialization
Citations

This map shows the geographic impact of Amy J. Eisenfeld's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy J. Eisenfeld with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy J. Eisenfeld more than expected).

Fields of papers citing papers by Amy J. Eisenfeld

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy J. Eisenfeld. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy J. Eisenfeld. The network helps show where Amy J. Eisenfeld may publish in the future.

Co-authorship network of co-authors of Amy J. Eisenfeld

This figure shows the co-authorship network connecting the top 25 collaborators of Amy J. Eisenfeld. A scholar is included among the top collaborators of Amy J. Eisenfeld based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy J. Eisenfeld. Amy J. Eisenfeld is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Robak, Tadeusz, Andrzej Hellmann, Janusz Kłoczko, et al.. (2016). Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia. British Journal of Haematology. 176(4). 618–628. 30 indexed citations
2.
Gopal, Ajay K., Stefano Tarantolo, Naresh Bellam, et al.. (2014). Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. Investigational New Drugs. 32(6). 1213–1225. 19 indexed citations
3.
Pagel, John M., Stephen E. Spurgeon, John C. Byrd, et al.. (2014). Otlertuzumab (TRU‐016), an anti‐CD37 monospecific ADAPTIR™ therapeutic protein, for relapsed or refractory NHL patients. British Journal of Haematology. 168(1). 38–45. 34 indexed citations
4.
Byrd, John C., John M. Pagel, Farrukh T. Awan, et al.. (2014). A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood. 123(9). 1302–1308. 56 indexed citations
5.
6.
Paz‐Ares, Luis, Helen J. Ross, Mary O’Brien, et al.. (2008). Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. British Journal of Cancer. 98(10). 1608–1613. 125 indexed citations
7.
Mita, Monica, Alain C. Mita, John Sarantopoulos, et al.. (2008). Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies. Cancer Chemotherapy and Pharmacology. 64(2). 287–295. 23 indexed citations
8.
9.
Verschraegen, Claire F., Keith M. Skubitz, Adil Daud, et al.. (2008). A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 63(5). 903–910. 29 indexed citations
10.
DiPetrillo, Thomas A., Devon Evans, Paul Akerman, et al.. (2007). Paclitaxel poliglumex (PPX), cisplatin and concurrent radiation for esophageal and gastric cancer: A phase I study. Journal of Clinical Oncology. 25(18_suppl). 15130–15130. 2 indexed citations
11.
Homsi, Jade, George R. Simon, Chris R. Garrett, et al.. (2007). Phase I Trial of Poly-l-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 13(19). 5855–5861. 74 indexed citations
12.
Nemunaitis, John, Casey Cunningham, Neil Senzer, et al.. (2005). Phase I Study of CT-2103, A Polymer-Conjugated Paclitaxel, and Carboplatin in Patients with Advanced Solid Tumors. Cancer Investigation. 23(8). 671–676. 32 indexed citations
13.
Sabbatini, Paul, Carol Aghajanian, Don S. Dizon, et al.. (2004). Phase II Study of CT-2103 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma. Journal of Clinical Oncology. 22(22). 4523–4531. 91 indexed citations
14.
15.
Quay, Steven C. & Amy J. Eisenfeld. (1997). Safety assessment of the use of perflenapent emulsion for contrast enhancement of echocardiography and diagnostic radiology ultrasound studies. Clinical Cardiology. 20(S1). 19–26. 8 indexed citations
16.
Eisenfeld, Amy J., Ann H. Bunt-Milam, & John C. Saari. (1987). Uveoretinitis in rabbits following immunization with interphotoreceptor retinoid-binding protein. Experimental Eye Research. 44(3). 425–438. 36 indexed citations
17.
Eisenfeld, Amy J., Ann H. Bunt-Milam, & J C Saari. (1985). Immunocytochemical localization of interphotoreceptor retinoid-binding protein in developing normal and RCS rat retinas.. PubMed. 26(5). 775–8. 41 indexed citations
18.
Eisenfeld, Amy J., Ann H. Bunt-Milam, & John C. Saari. (1985). Localization of retinoid-binding proteins in developing rat retina. Experimental Eye Research. 41(3). 299–304. 43 indexed citations
19.
Eisenfeld, Amy J., Matthew M. LaVail, & Jennifer H. LaVail. (1984). Assessment of possible transneuronal changes in the retina of rats with inherited retinal dystrophy: Cell size, number, synapses, and axonal transport by retinal ganglion cells. The Journal of Comparative Neurology. 223(1). 22–34. 56 indexed citations
20.
Eisenfeld, Amy J., Ann H. Bunt-Milam, & P. Vijay Sarthy. (1984). Müller cell expression of glial fibrillary acidic protein after genetic and experimental photoreceptor degeneration in the rat retina.. PubMed. 25(11). 1321–8. 247 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aneeka Chaudhry Breakdown of academic impact, for papers by Shimpei Nishikawa Breakdown of academic impact, for papers by José Courty Breakdown of academic impact, for papers by Michael D. Barker Breakdown of academic impact, for papers by Mauricio Rosenfeld Breakdown of academic impact, for papers by Anthony M.P. Montgomery Breakdown of academic impact, for papers by Bithiah Grace Jaganathan Breakdown of academic impact, for papers by Zahra‐Soheila Soheili Breakdown of academic impact, for papers by Jung Min Lee Breakdown of academic impact, for papers by S. Clifford Schold
Rankless by CCL
2026